[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 18, Issue 2 (Summer 2021) ::
Sci J Iran Blood Transfus Organ 2021, 18(2): 79-86 Back to browse issues page
Anti HLA Antibodies in Hemato-oncologic Patients with and without Platelet Refractoriness
M. Shaiegan, M. Mostakhdemin, M. Alaei , E. Ebrahinzadeh, A. Chegini, S. Mohammadi
Abstract:   (343 Views)
Abstract
Background and Objectives
Various antibodies such as antibodies against RBC antigens, anti-HLA, and anti-platelet antibodies are developed after repeated blood transfusions and may lead to transfusion reactions such as platelet refractoriness in recipients. In this study, anti-HLA antibodies were evaluated in hemato-oncological patients, with and without simultaneous platelet refractoriness.
 
Materials and Methods
In this descriptive study, performed from 2017 to 2019, presence of anti-HLA antibodies in patients with hemato-oncological disorders, referred to the HSCT Research Center, Shariati Hospital, Tehran, was assessed using Panel Reactive Antibody (PRA) test based on complement lymphocytotoxicity. Data analysis was performed by SPSS (version 16) and chi-square tests.
 
Results
Of 79 studied patients with hemato-oncological disorders including 34 females (43%) and 45 males (57%) with the age range of 2 to 83 years,  49 were platelet refractory and 30 were not. Anti-HLA antibodies were present in 39 (49.4%) patients and  40 (50.6%) were negative for them. The frequency of panel reactive antibody positive cases was significantly different between patients with platelet refractoriness (62.8%) and those without it (30%) (P = 0.007).
 
Conclusions 
The role of anti-HLA antibodies in platelet refractoriness is well established. Our study also showed a significant difference in this regard among two groups of hemato-oncological patients with and without platelet refractoriness. The presence of these antibodies does not always mean platelet refractoriness, and antibodies without the ability to activate complement can also cause this complication.
Keywords: Platelets, Histocompatibility Antigens, HLA
Full-Text [PDF 485 kb]   (113 Downloads) |   |   Full-Text (HTML)  (175 Views)  
Type of Study: Research | Subject: Blood transfusion medicine
Published: 2021/07/1
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shaiegan M, Mostakhdemin M, Alaei M, Ebrahinzadeh E, Chegini A, Mohammadi S. Anti HLA Antibodies in Hemato-oncologic Patients with and without Platelet Refractoriness. Sci J Iran Blood Transfus Organ. 2021; 18 (2) :79-86
URL: http://bloodjournal.ir/article-1-1396-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 18, Issue 2 (Summer 2021) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.06 seconds with 31 queries by YEKTAWEB 4341